Article
PrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up.
Oncogene - 1 Sept 2024
Lailler Claire, Didelot Audrey, Garinet Simon, Berthou Hugo, Sroussi Marine, de Reyniès Aurélien, Dedhar Shoukat, Martin-Lannerée Séverine, Fabre Elizabeth, Le Pimpec-Barthes Françoise, Perrier Alexandre, Poindessous Virginie, Mansuet-Lupo Audrey, Djouadi Fatima, Launay Jean-Marie, Laurent-Puig Pierre, Blons Hélène, Mouillet-Richard Sophie
Abstract excerpt
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) benefit from treatment with tyrosine kinase inhibitors (TKI) targeting EGFR. Despite improvements in patient care, especially with the 3rd generation TKI osimertinib, disease relapse is observed in all patients. Among the various processes involved in TKI resistance, epithelial-to-mesenchymal transition (EMT) is far from being fully characterized. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.